Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.68 USD | +5.90% | +0.56% | -17.28% |
Mar. 21 | Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q4 Revenue $1.5M | MT |
Mar. 21 | Armata Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Business Summary
Number of employees: 66
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pathogen-specific Bacteriophage Therapeutics
100.0
%
| 6 | 100.0 % | 5 | 100.0 % | -17.77% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States and Australia
100.0
%
| 6 | 100.0 % | 5 | 100.0 % | -17.77% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Deborah Birx
CEO | Chief Executive Officer | 68 | 23-07-10 |
Mina Pastagia
CTO | Chief Tech/Sci/R&D Officer | - | 20-10-25 |
Bryan Kadotani
PRN | Corporate Officer/Principal | - | - |
Richard Rychlik
AUD | Comptroller/Controller/Auditor | 68 | 23-09-04 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 64 | 20-02-11 | |
Joseph Patti
BRD | Director/Board Member | 60 | 19-05-08 |
Jules Haimovitz
BRD | Director/Board Member | 73 | 21-03-31 |
Odysseas Kostas
BRD | Director/Board Member | 49 | 20-02-11 |
Robin Kramer
CHM | Chairman | 58 | 20-12-07 |
Todd Peterson
BRD | Director/Board Member | 66 | 19-10-09 |
Deborah Birx
CEO | Chief Executive Officer | 68 | 23-07-10 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 36,148,539 | 10,719,501 ( 29.65 %) | 0 | 29.65 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.28% | 91.48M | |
+1.96% | 42.59B | |
+8.02% | 40.65B | |
+49.22% | 40.57B | |
-12.36% | 26.77B | |
+9.19% | 24.81B | |
-24.41% | 18.17B | |
+28.47% | 12.05B | |
-3.26% | 11.7B | |
+6.96% | 11.1B |
- Stock Market
- Equities
- ARMP Stock
- Company Armata Pharmaceuticals, Inc.